nach oben

Current Urology Reports

Erschienen in:

01.12.2017 | Lower Urinary Tract Symptoms & Voiding Dysfunction (J Sandhu, Section Editor)

New Devices and Technologies for the Management of Overactive Bladder

verfasst von: Juan M. Guzman-Negron, Howard B. Goldman

Erschienen in: Current Urology Reports | Ausgabe 12/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Overactive bladder (OAB) affects millions of people in the USA and has a significant impact on their quality of life. Despite having a number of safe and effective ways of managing refractory OAB patients, there are many promising new technologies actively being studied and developed for the treatment of this population. This review examines current new devices and technologies under study for the treatment of OAB.

Recent Findings

Modifications to already established therapies such as sacral nerve stimulation (SNS) or tibial nerve stimulation (TNS) are currently being studied for refractory OAB. On the SNS front, a newly rechargeable, smaller neurostimulator has been developed and has shown promising results for the treatment of refractory OAB. There are two newly implantable TNS devices actively being studied for the treatment of refractory OAB. These implanted TNS systems will allow the patient to receive treatment from the comfort of their home without the need for frequent office visits. Most recently, radiofrequency ablation intravesical therapy has been proposed as a newer technology with the potential to reduce OAB symptoms.

Summary

There are many new technologies actively being studied and developed for the management of refractory OAB patients. If shown to be safe and efficacious, these therapies may one day alter our current management of patients with OAB.

Tubaro A. Defining overactive bladder: Epidemiology and burden of disease. Urology. 2004;64(6 Supplement 1):2–6.CrossRefPubMed

Peters KM, Carrico DJ, Perez-Marrero RA, Khan AU, Wooldridge LS, Davis GL, et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. 2010;183:1438–43.CrossRefPubMed

Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, Das AK, Foster Jr HE, Scarpero HM, Tessier CD, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. American Urological Association 2014.

Brubaker L, Fanning K, Goldberg EL, Benner JS, Trocio JN, Bavendam T, et al. Predictors of discontinuing overactive bladder medications. BJU Int. 2010;105(9):1283–90.CrossRefPubMed

Madhuvrata P, Cody JD, Ellis G, Herbison GP, Hay-Smith EJ. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev. 2012;1:CD005429.PubMed

Peters KM, Carrico DJ, MacDiarmid SA, Wooldridge LS, Khan AU, Franco N, et al. Sustained therapeutic effects of percutaneous tibial nerve stimulation: 24-month results of the STEP study. Neurourol Urodyn. 2013;32:24–9.CrossRefPubMed

Sussman D, Yehoshua A, Kowalski J, Lee W, Kish J, Chaudhari S, et al. Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real-world claims data analysis. Int J Clin Pract. 2017;71:3–4.CrossRef

Siegel S, Noblett K, Mangel J, Griebling TL, Sutherland SE, Bird ET, et al. Three year follow-up results of a prospective, multicenter study in overactive bladder subjects treated with sacral neuromodulation. Urology. 2016;94:57–63.CrossRefPubMed

• Van Kerrebroeck P, Blok B, De Wachter S, Ruffion A, Van der Aa F, Perrouin-Verbe MA, et al. A prospective multicenter clinical study evaluating a miniaturized, rechargeable sacral neuromodulation system for the safe and effective treatment of overactive bladder. Neurourol Urodynamics. 2017;36(S3):S32–3. This prospective study highlights the safety and short-term efficacy of a newly rechargeable sacral neuromodulation therapy system

10.

Deer T, Pope J, Benyamin R, Vallejo R, Friedman A, Caraway D, et al. Prospective, multicenter, randomized, double-blinded, partial crossover study to assess the safety and efficacy of the novel neuromodulation system in the treatment of patients with chronic pain of peripheral nerve origin. Neuromodulation. 2016;19(1):91–100.CrossRefPubMed

11.

Dmochowski R. Prospective, multi-center, randomized, double-blinded trial of percutaneous tibial nerve stimulation with the bioness stimrouter neuromodulation system versus sham in the treatment of overactive bladder. clinicaltrials.gov 2017.

12.

• Heesakkers J, van Breda H, Van Kerrebroeck P, Digesu A, Elneil S. Safety and performance of a wireless implantable tibial nerve stimulator device for the treatment of patients with overactive bladder. Neurourol Urodynamics. 2016;35(S4):S45–6. This prospective study provides evidence of the safety, efficacy, and feasibility of implanting a small wireless tibial neurostimulator intended for home care use in the treatment of overactive bladder

13.

Dmochowski R. Cystoscopic ablation via RF energy Clinical Trial. clinicaltrials.gov 2017.

14.

Rovner E. Cystoscopic ablation via RF energy Clinical Trial (Caret 2). clinicaltrials.gov 2017.

Titel: New Devices and Technologies for the Management of Overactive Bladder
verfasst von: Juan M. Guzman-Negron
Howard B. Goldman
Publikationsdatum: 01.12.2017
Verlag: Springer US
Erschienen in: Current Urology Reports / Ausgabe 12/2017
Print ISSN: 1527-2737
Elektronische ISSN: 1534-6285
DOI: https://doi.org/10.1007/s11934-017-0739-y

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2017

Predictability and Practicality of Image-Based Scoring Systems for Patient Assessment and Outcome Stratification During Percutaneous Nephrolithotomy: a Contemporary Update

Spatial Tracking of Targeted Prostate Biopsy Locations: Moving Towards Effective Focal Partial Prostate Gland Ablation with Improved Treatment Planning

Systematic Review of Studies Reporting Positive Surgical Margins After Bladder Neck Sparing Radical Prostatectomy

HistoScanningTM to Detect and Characterize Prostate Cancer—a Review of Existing Literature

Aquablation of the Prostate for Symptomatic Benign Prostatic Hyperplasia: Early Results